Antineoplaston Therapy in Treating Patients With Primary Liver Cancer

Status Terminated

Clinical Trial Summary

Current therapies for Primary Liver Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Primary Liver Cancer.

PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with advanced Head and Neck Cancer.

Clinical Trial Description

Primary Liver Cancer patients receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues up to 12 months in the absence of disease progression or unacceptable toxicity.

OBJECTIVES:

- To determine the efficacy of Antineoplaston therapy in patients with advanced Primary Liver Cancer, as measured by an objective response to therapy (complete response, partial response or stable disease).

- To determine the safety and tolerance of Antineoplaston therapy in patients with advanced Primary Liver Cancer.

- To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00003530
Study type	Interventional
Source	Burzynski Research Institute
Contact
Status	Terminated
Phase	Phase 2
Start date	March 21, 1977
Completion date	October 17, 1999

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03161925` - Chinese Liver Cancer Clinical Survey	N/A
Completed	`NCT00261378` - Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation	Phase 2
Enrolling by invitation	`NCT05609448` - MRI-guided Holmium-166 Radioembolization	N/A
Recruiting	`NCT05714124` - Liver Embolization Approaches for Tumor Management
Not yet recruiting	`NCT05353894` - Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers	Phase 1
Completed	`NCT03518632` - Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE)	N/A
Recruiting	`NCT04806464` - Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer	Phase 1
Recruiting	`NCT06342414` - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Completed	`NCT01116804` - Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)	Phase 1
Recruiting	`NCT03067493` - RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial	Phase 2
Completed	`NCT05183776` - Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT	N/A
Recruiting	`NCT05677724` - Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
Not yet recruiting	`NCT03178929` - Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma	N/A
Recruiting	`NCT05267080` - Registry on Percutaneous Electrochemotherapy
Not yet recruiting	`NCT02327819` - The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer	N/A
Completed	`NCT01640522` - Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms	N/A
Completed	`NCT00408122` - Evaluation of Preoperative Investigations in Patients With Liver Cancer	N/A
Recruiting	`NCT03297255` - Primary Liver Cancer Cohort of South China	N/A
Recruiting	`NCT06325267` - Clinical Characteristics of Primary Liver Cancer
Completed	`NCT04295330` - Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy	N/A